Underreporting of drug industry payments to patient organisations in the UK (2012-2016)

This online dataset comprises web supplements (WS) accompanying the paper entitled “An underreported relationship: a comparative study of pharmaceutical industry and patient organisation payment disclosures in the UK (2012-2016)”. The dataset includes aggregated information from 1. yearly disclosure reports published by 63 UK-based drug companies including payments made to patient organisations; 2. yearly financial accounts produced by 200 UK-based charities and published on charity regulator websites. The data is divided into web supplements 3-20 which are signposted throughout the Results section of the above-mentioned article as “web supplement XX”

Dataset for "A patient-industry complex? Investigating the financial dependency of UK patient organisations on drug company funding"

This digital dataset includes Appendices accompanying the paper entitled ‘A “patient-industry complex”? Investigating the financial dependency of UK patient organisations on drug company funding (2012-2016)’. The Appendices provide (1) raw data analysed in the paper; (2) background details of data collection and analysis; (3) additional research findings and commentary. The Appendices draw on data extracted from two sources: A. Yearly disclosure reports published by 62 UK-based drug companies, on their respective websites, including payments made to patient organisations registered as charities in the UK; B. Yearly financial accounts produced by 399 UK-based patient organisations and published on charity regulator websites. The data is divided into Appendices which are signposted throughout the Methods and Findings sections of the above-mentioned article

Lessons learnt from the application of the HEcoPerMed guidance to three modelling case studies - Supplementary material

Appendix Table 1 Recommendations of the Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine applied in the NTRK case studyAppendix Table 2 Recommendations of the Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine applied in the ToxNav case studyAppendix Table 3 Recommendations of the Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine applied in the MODY case stud

Lessons learnt from the application of the HEcoPerMed guidance to three modelling case studies - Supplementary material

Appendix Table 1 Recommendations of the Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine applied in the NTRK case studyAppendix Table 2 Recommendations of the Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine applied in the ToxNav case studyAppendix Table 3 Recommendations of the Guidance for the Harmonisation and Improvement of Economic Evaluations of Personalised Medicine applied in the MODY case stud

Cost-effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK - Supplementary material

Appendix Table 1 Age and sex specific mortality rates and population utility in the Netherlands and United Kingdo

Cost-effectiveness of extended DPYD testing before fluoropyrimidine chemotherapy in metastatic breast cancer in the UK - Supplementary material

Appendix Table 1 Age and sex specific mortality rates and population utility in the Netherlands and United Kingdo

Budget impact and transferability of cost-effectiveness of DPYD testing in metastatic breast cancer in 3 health systems - supplementary material

Appendix Table 1. General (UK) model input parameter

Budget impact and transferability of cost-effectiveness of DPYD testing in metastatic breast cancer in 3 health systems - supplementary material

Appendix Table 1. General (UK) model input parameter

Cost-effectiveness of alternative NTRK-testing strategies and histology-independent therapy entrectinib in 3 countries - supplementary material

Table S1. Test groups, proportional distribution umour type distribution before NTRK gene fusion testing, NTRK prevalence and tumour type distribution in entrectinib trials.Table S2. Sensitivity and specificity of immunohistochemistry (IHC) tests by tumour type.Table S3. Number of patients and parametric distributions with the lowest AIC for overall survival (OS) and time to treatment discontinuation (TTD)Table S4. Costs of biopsy, IHC, and RNA-NGS by tumour type and country.Table S5. Standard of care treatments by cancer typeTable S6. Costs of standard of care (SoC) treatment and adverse event treatment by tumour type and country.Table S7. Probability distributions used for probabilistic sensitivity analysis (PSA)Table S8. Incremental budget impact according to time horizon of national HTA guidelinesFigure S1. Model structureFigure S2. Results of the univariate sensitivity analysi

Cost-effectiveness of genetic based screening strategies for Maturity Onset Diabetes of the Young (MODY) - Supplementary Material

Article appendi